Turning over renal osteodystrophy dogma: direct actions of FGF23 on osteoblast β-catenin pathway.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 27312441.
- Also identified by DOI 10.1016/j.kint.2016.03.028.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although recognized as a major complication of chronic kidney disease (CKD), the pathophysiology of the CKD-related mineral and bone disorder (CKD-MBD) is not completely understood. Recently, the inhibition of Wnt/β-catenin pathway in osteocytes by sclerostin has been shown to play a role in CKD-MBD. The study by Carrilo-Lopez et al. confirms this inhibition in an experimental model of CKD. Moreover, they describe direct actions of FGF23-Klotho on osteoblasts, increasing the expression of DKK1, another Wnt/β-catenin pathway inhibitor.
Medical subject headings
- Chronic Kidney Disease-Mineral and Bone Disorder
- beta Catenin